Woodmont Investment Counsel LLC Boosts Holdings in Harrow, Inc. (NASDAQ:HROW)

Woodmont Investment Counsel LLC increased its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 27.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,693 shares of the company's stock after acquiring an additional 22,293 shares during the quarter. Woodmont Investment Counsel LLC owned about 0.29% of Harrow worth $2,758,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HROW. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after acquiring an additional 29,262 shares during the last quarter. GAMMA Investing LLC grew its position in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after purchasing an additional 6,027 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after buying an additional 22,266 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Harrow by 8.4% during the fourth quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock worth $2,900,000 after buying an additional 6,690 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Stock Performance

Shares of NASDAQ:HROW traded up $0.71 during trading on Tuesday, hitting $31.71. 357,552 shares of the stock traded hands, compared to its average volume of 496,224. The company has a quick ratio of 0.85, a current ratio of 0.91 and a debt-to-equity ratio of 2.01. The company has a fifty day moving average price of $27.01 and a two-hundred day moving average price of $29.14. Harrow, Inc. has a 52-week low of $20.36 and a 52-week high of $59.23. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -56.62 and a beta of 0.40.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. The firm had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. As a group, equities analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HROW. William Blair initiated coverage on Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating on the stock. B. Riley dropped their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. HC Wainwright increased their price objective on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Finally, BTIG Research started coverage on shares of Harrow in a research report on Thursday, June 12th. They set a "buy" rating and a $62.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $61.40.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.